Abbott has disclosed a cybersecurity incident involving unauthorized access to a limited number of internal systems used by its Cancer Diagnostics business.
Upon discovering the activity, the company acted swiftly by launching an investigation, engaging external cybersecurity experts, and coordinating with law enforcement agencies.
Abbott Confirms Cyberattack
According to Abbott’s statement released on July 16, 2026, this incident is restricted to the Cancer Diagnostics environment.
Importantly, the company reported that there was no impact on its broader operational technology and business infrastructure, which includes manufacturing, laboratory operations, patient services, products, and product availability.
Abbott did not identify the threat actor, the method of intrusion, the types of affected systems, the timeline of unauthorized access, or whether there was any ransomware, data encryption, or data exfiltration.
Abbott clarified that its legacy Exact Sciences systems are separate from its infrastructure and were not involved in the reported incident. This distinction is crucial because cancer diagnostics platforms often handle highly sensitive information, including clinical testing data, laboratory workflows, physician requests, and patient records.
As of now, Abbott has not confirmed whether any personal health information, protected health information, customer data, employee records, or proprietary business information was accessed or removed.
“Abbott is investigating a cyber incident involving unauthorized access to a limited number of internal systems in our Cancer Diagnostics business only,” the company stated. “We have engaged leading third-party cybersecurity experts and law enforcement and are working diligently to investigate the information accessed and resolve this issue.”
Healthcare and diagnostic organizations are attractive targets for cybercriminals due to their reliance on continuous operations, interconnected laboratory systems, and sensitive medical data, alongside time-critical patient services.
A compromise affecting diagnostic networks could introduce risks including data theft, account misuse, operational disruption, delayed test processing, and concerns regarding the integrity of laboratory information workflows. However, Abbott’s statement indicates that no such operational effects have been observed so far.
The company does not currently expect the security incident to have a material business or financial impact. Abbott is actively monitoring its systems as the investigation continues.
Their response indicates that they have activated incident-response procedures, which typically include forensic examinations, access reviews, containment measures, log analysis, credential resets, and assessments of potentially accessed data.
Organizations working with Abbott Cancer Diagnostics systems should remain vigilant for any future notifications regarding data exposure, credential security, or related service impacts.
Healthcare providers and laboratory partners are encouraged to review account activity, enforce multi-factor authentication, monitor for phishing attempts related to the incident, and ensure that communications claiming to originate from Abbott are verified through official channels.
Abbott has not yet released indicators of compromise, technical details, or a timeline for breach notifications. Further updates are expected to clarify the scope of the unauthorized access, the nature of the information involved, and whether affected individuals or partners will need to be notified.
Strengthen Your SOC by Accelerating Threat Detection & Rapid Investigations. -> Integrate ANY.RUN With Your SOC Now.
